Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 240

1.

Evolutionary history of human colitis-associated colorectal cancer.

Baker AM, Cross W, Curtius K, Al Bakir I, Choi CR, Davis HL, Temko D, Biswas S, Martinez P, Williams MJ, Lindsay JO, Feakins R, Vega R, Hayes SJ, Tomlinson IPM, McDonald SAC, Moorghen M, Silver A, East JE, Wright NA, Wang LM, Rodriguez-Justo M, Jansen M, Hart AL, Leedham SJ, Graham TA.

Gut. 2019 Jun;68(6):985-995. doi: 10.1136/gutjnl-2018-316191. Epub 2018 Jul 10.

2.

The Effect of Physicochemical Modification on the Function of Antibodies Induced by Anti-Nicotine Vaccine in Mice.

Thorn JM, Bhattacharya K, Crutcher R, Sperry J, Isele C, Kelly B, Yates L, Zobel J, Zhang N, Davis HL, McCluskie MJ.

Vaccines (Basel). 2017 May 17;5(2). pii: E11. doi: 10.3390/vaccines5020011.

3.

Immunogenicity of a peptide-based anti-IgE conjugate vaccine in non-human primates.

Weeratna RD, Chikh G, Zhang L, Fraser JD, Thorn JM, Merson JR, McCluskie MJ, Champion BR, Davis HL.

Immun Inflamm Dis. 2016 Apr 1;4(2):135-147. eCollection 2016 Jun.

4.

Effects of KLK Peptide on Adjuvanticity of Different ODN Sequences.

Chikh G, Luu R, Patel S, Davis HL, Weeratna RD.

Vaccines (Basel). 2016 May 4;4(2). pii: E14. doi: 10.3390/vaccines4020014.

5.

The effect of preexisting anti-carrier immunity on subsequent responses to CRM197 or Qb-VLP conjugate vaccines.

McCluskie MJ, Evans DM, Zhang N, Benoit M, McElhiney SP, Unnithan M, DeMarco SC, Clay B, Huber C, Deora A, Thorn JM, Stead DR, Merson JR, Davis HL.

Immunopharmacol Immunotoxicol. 2016 Jun;38(3):184-96. doi: 10.3109/08923973.2016.1165246. Epub 2016 Apr 27.

PMID:
27121368
6.

CpG-mediated augmentation of CD8+ T-cell responses in mice is attenuated by a water-in-oil emulsion (Montanide ISA-51) but enhanced by an oil-in-water emulsion (IDRI SE).

Makinen SR, Zhu Q, Davis HL, Weeratna RD.

Int Immunol. 2016 Sep;28(9):453-61. doi: 10.1093/intimm/dxw017. Epub 2016 Apr 7.

PMID:
27055469
7.

Support for the revocation of general safety test regulations in biologics license applications.

Evans DM, Thorn JM, Arch-Douglas K, Sperry JB, Thompson B, Davis HL, McCluskie MJ.

Biologicals. 2016 May;44(3):178-81. doi: 10.1016/j.biologicals.2016.02.001. Epub 2016 Mar 17.

PMID:
26996102
8.

Anti-IgE Qb-VLP Conjugate Vaccine Self-Adjuvants through Activation of TLR7.

Akache B, Weeratna RD, Deora A, Thorn JM, Champion B, Merson JR, Davis HL, McCluskie MJ.

Vaccines (Basel). 2016 Jan 21;4(1). pii: E3. doi: 10.3390/vaccines4010003.

9.

Combination therapy including CpG oligodeoxynucleotides and entecavir induces early viral response and enhanced inhibition of viral replication in a woodchuck model of chronic hepadnaviral infection.

Meng Z, Zhang X, Pei R, Zhang E, Kemper T, Vollmer J, Davis HL, Glebe D, Gerlich W, Roggendorf M, Lu M.

Antiviral Res. 2016 Jan;125:14-24. doi: 10.1016/j.antiviral.2015.11.001. Epub 2015 Nov 14.

PMID:
26585244
10.

Anti-nicotine vaccines: Comparison of adjuvanted CRM197 and Qb-VLP conjugate formulations for immunogenicity and function in non-human primates.

McCluskie MJ, Thorn J, Gervais DP, Stead DR, Zhang N, Benoit M, Cartier J, Kim IJ, Bhattacharya K, Finneman JI, Merson JR, Davis HL.

Int Immunopharmacol. 2015 Dec;29(2):663-671. doi: 10.1016/j.intimp.2015.09.012. Epub 2015 Sep 26.

PMID:
26404190
11.

Molecular attributes of conjugate antigen influence function of antibodies induced by anti-nicotine vaccine in mice and non-human primates.

McCluskie MJ, Thorn J, Mehelic PR, Kolhe P, Bhattacharya K, Finneman JI, Stead DR, Piatchek MB, Zhang N, Chikh G, Cartier J, Evans DM, Merson JR, Davis HL.

Int Immunopharmacol. 2015 Apr;25(2):518-27. doi: 10.1016/j.intimp.2015.02.030. Epub 2015 Feb 28.

PMID:
25737198
12.

Selection of a novel anti-nicotine vaccine: influence of antigen design on antibody function in mice.

Pryde DC, Jones LH, Gervais DP, Stead DR, Blakemore DC, Selby MD, Brown AD, Coe JW, Badland M, Beal DM, Glen R, Wharton Y, Miller GJ, White P, Zhang N, Benoit M, Robertson K, Merson JR, Davis HL, McCluskie MJ.

PLoS One. 2013 Oct 1;8(10):e76557. doi: 10.1371/journal.pone.0076557. eCollection 2013.

13.

CpG ODN and ISCOMATRIX adjuvant: a synergistic adjuvant combination inducing strong T-Cell IFN-γ responses.

McCluskie MJ, Weeratna RD, Evans DM, Makinen S, Drane D, Davis HL.

Biomed Res Int. 2013;2013:636847. doi: 10.1155/2013/636847. Epub 2013 Mar 23.

14.

Enhancing immunogenicity of a 3'aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates.

McCluskie MJ, Pryde DC, Gervais DP, Stead DR, Zhang N, Benoit M, Robertson K, Kim IJ, Tharmanathan T, Merson JR, Davis HL.

Int Immunopharmacol. 2013 May;16(1):50-6. doi: 10.1016/j.intimp.2013.03.021. Epub 2013 Apr 2.

PMID:
23562759
15.

Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909.

Kuball J, de Boer K, Wagner E, Wattad M, Antunes E, Weeratna RD, Vicari AP, Lotz C, van Dorp S, Hol S, Greenberg PD, Heit W, Davis HL, Theobald M.

Cancer Immunol Immunother. 2011 Feb;60(2):161-71. doi: 10.1007/s00262-010-0929-7. Epub 2010 Oct 21.

16.

A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge.

Buchman GW, Cohen ME, Xiao Y, Richardson-Harman N, Silvera P, DeTolla LJ, Davis HL, Eisenberg RJ, Cohen GH, Isaacs SN.

Vaccine. 2010 Sep 14;28(40):6627-36. doi: 10.1016/j.vaccine.2010.07.030. Epub 2010 Jul 24.

17.

Medicine and the arts. Sickle cell vision: A patient's photographic illustration of coping [excerpt] by Heather L. Davis. Commentary.

Ross PT, Davis HL, Kumagai AK, Campbell AD, Lypson ML.

Acad Med. 2010 Jul;85(7):1210-1. doi: 10.1097/ACM.0b013e3181e2b66b. No abstract available.

PMID:
20592518
18.

Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial.

Søgaard OS, Lohse N, Harboe ZB, Offersen R, Bukh AR, Davis HL, Schønheyder HC, Østergaard L.

Clin Infect Dis. 2010 Jul 1;51(1):42-50. doi: 10.1086/653112.

PMID:
20504165
19.

Immunostimulatory effects of three classes of CpG oligodeoxynucleotides on PBMC from HCV chronic carriers.

Cooper CL, Ahluwalia NK, Efler SM, Vollmer J, Krieg AM, Davis HL.

J Immune Based Ther Vaccines. 2008 Jun 9;6:3. doi: 10.1186/1476-8518-6-3.

20.

CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years.

Cooper CL, Angel JB, Seguin I, Davis HL, Cameron DW.

Clin Infect Dis. 2008 Apr 15;46(8):1310-4. doi: 10.1086/533467.

PMID:
18444872
21.
22.

Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus.

McHutchison JG, Bacon BR, Gordon SC, Lawitz E, Shiffman M, Afdhal NH, Jacobson IM, Muir A, Al-Adhami M, Morris ML, Lekstrom-Himes JA, Efler SM, Davis HL.

Hepatology. 2007 Nov;46(5):1341-9.

PMID:
17929306
23.

Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist.

Vicari AP, Schmalbach T, Lekstrom-Himes J, Morris ML, Al-Adhami MJ, Laframboise C, Leese P, Krieg AM, Efler SM, Davis HL.

Antivir Ther. 2007;12(5):741-51.

PMID:
17713157
24.

A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost.

Xiao Y, Aldaz-Carroll L, Ortiz AM, Whitbeck JC, Alexander E, Lou H, Davis HL, Braciale TJ, Eisenberg RJ, Cohen GH, Isaacs SN.

Vaccine. 2007 Jan 26;25(7):1214-24. Epub 2006 Oct 17.

25.

Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide.

Mullen GE, Giersing BK, Ajose-Popoola O, Davis HL, Kothe C, Zhou H, Aebig J, Dobrescu G, Saul A, Long CA.

Vaccine. 2006 Mar 24;24(14):2497-505. Epub 2006 Jan 4.

PMID:
16434128
26.

Testing of CpG-optimized protein and DNA vaccines against the hepatitis B virus in chimpanzees for immunogenicity and protection from challenge.

Payette PJ, Ma X, Weeratna RD, McCluskie MJ, Shapiro M, Engle RE, Davis HL, Purcell RH.

Intervirology. 2006;49(3):144-51.

PMID:
16428890
27.

Treatment of intravaginal HSV-2 infection in mice: a comparison of CpG oligodeoxynucleotides and resiquimod (R-848).

McCluskie MJ, Cartier JL, Patrick AJ, Sajic D, Weeratna RD, Rosenthal KL, Davis HL.

Antiviral Res. 2006 Feb;69(2):77-85. Epub 2005 Dec 5.

PMID:
16377001
28.

CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults.

Cooper CL, Davis HL, Angel JB, Morris ML, Elfer SM, Seguin I, Krieg AM, Cameron DW.

AIDS. 2005 Sep 23;19(14):1473-9.

PMID:
16135900
29.

TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).

Weeratna RD, Makinen SR, McCluskie MJ, Davis HL.

Vaccine. 2005 Nov 1;23(45):5263-70. Epub 2005 Jul 18.

PMID:
16081189
30.
31.

Enhanced HIV-1 specific immune response by CpG ODN and HIV-1 immunogen-pulsed dendritic cells confers protection in the Trimera murine model of HIV-1 infection.

Ayash-Rashkovsky M, Borkow G, Davis HL, Moss RB, Bartholomew R, Bentwich Z.

FASEB J. 2005 Jul;19(9):1152-4. Epub 2005 Apr 15. Erratum in: FASEB J. 2005 Jul;19(9):1 p following 1154. Moss, Ronnald B [corrected to Moss, Ronald B].

PMID:
15833766
32.

Biodistribution and metabolism of immunostimulatory oligodeoxynucleotide CPG 7909 in mouse and rat tissues following subcutaneous administration.

Noll BO, McCluskie MJ, Sniatala T, Lohner A, Yuill S, Krieg AM, Schetter C, Davis HL, Uhlmann E.

Biochem Pharmacol. 2005 Mar 15;69(6):981-91.

PMID:
15748709
33.

CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study.

Cooper CL, Davis HL, Morris ML, Efler SM, Adhami MA, Krieg AM, Cameron DW, Heathcote J.

J Clin Immunol. 2004 Nov;24(6):693-701.

PMID:
15622454
34.

Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response.

Siegrist CA, Pihlgren M, Tougne C, Efler SM, Morris ML, AlAdhami MJ, Cameron DW, Cooper CL, Heathcote J, Davis HL, Lambert PH.

Vaccine. 2004 Dec 16;23(5):615-22.

PMID:
15542181
36.

Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation.

Vollmer J, Weeratna RD, Jurk M, Samulowitz U, McCluskie MJ, Payette P, Davis HL, Schetter C, Krieg AM.

Immunology. 2004 Oct;113(2):212-23.

37.

Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine.

Cooper CL, Davis HL, Morris ML, Efler SM, Krieg AM, Li Y, Laframboise C, Al Adhami MJ, Khaliq Y, Seguin I, Cameron DW.

Vaccine. 2004 Aug 13;22(23-24):3136-43.

PMID:
15297066
38.

Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.

Vollmer J, Weeratna RD, Jurk M, Davis HL, Schetter C, Wüllner M, Wader T, Liu M, Kritzler A, Krieg AM.

J Leukoc Biol. 2004 Sep;76(3):585-93. Epub 2004 Jun 24.

PMID:
15218053
39.

Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.

Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M, Wader T, Tluk S, Liu M, Davis HL, Krieg AM.

Eur J Immunol. 2004 Jan;34(1):251-62.

40.

Parameters of CpG oligodeoxynucleotide-induced protection against intravaginal HSV-2 challenge.

Sajic D, Ashkar AA, Patrick AJ, McCluskie MJ, Davis HL, Levine KL, Holl R, Rosenthal KL.

J Med Virol. 2003 Dec;71(4):561-8.

PMID:
14556270
41.

CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB/c mice.

Weeratna R, Comanita L, Davis HL.

Immunol Cell Biol. 2003 Feb;81(1):59-62.

PMID:
12534947
42.

History of vaccines and positioning of current trends.

Payette PJ, Davis HL.

Curr Drug Targets Infect Disord. 2001 Nov;1(3):241-7.

PMID:
12455398
43.

Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge.

Dumais N, Patrick A, Moss RB, Davis HL, Rosenthal KL.

J Infect Dis. 2002 Oct 15;186(8):1098-105. Epub 2002 Sep 30.

PMID:
12355360
44.

DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice.

Ma X, Forns X, Gutierrez R, Mushahwar IK, Wu T, Payette PJ, Bukh J, Purcell RH, Davis HL.

Vaccine. 2002 Sep 10;20(27-28):3263-71.

PMID:
12213395
46.

Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA.

McCluskie MJ, Weeratna RD, Payette PJ, Davis HL.

FEMS Immunol Med Microbiol. 2002 Feb 18;32(3):179-85.

47.

The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant.

Choi AH, McNeal MM, Flint JA, Basu M, Lycke NY, Clements JD, Bean JA, Davis HL, McCluskie MJ, VanCott JL, Ward RL.

Vaccine. 2002 Mar 15;20(13-14):1733-40.

PMID:
11906760
48.
49.

Designing gene therapy vectors: avoiding immune responses by using tissue-specific promoters.

Weeratna RD, Wu T, Efler SM, Zhang L, Davis HL.

Gene Ther. 2001 Dec;8(24):1872-8.

50.

CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice.

Weeratna RD, Brazolot Millan CL, McCluskie MJ, Davis HL.

FEMS Immunol Med Microbiol. 2001 Dec;32(1):65-71.

Supplemental Content

Loading ...
Support Center